Trimel Pharmaceuticals Corporation (TSX:TRL) ("the "Company" or "Trimel") today announced the completion of enrolment and randomization of 304 patients in the Phase III clinical trial evaluating CompleoTRT™ in patients with male hypogonadism or more commonly referred to as "Low T".
Source:
www.marketwire.com/press-release/trimel-completes-patient-enrolment-of-compleotrt-phase-iii-trial-tsx-trl-1682482.htm
No comments:
Post a Comment